Bioprocess Solutions About Us

SGLS, denovoMATRIX Announce Investment, Expansion of Master Service Agreement

Saint-Gobain Life Sciences and denovoMATRIX Announce Investment and Expansion of Master Service Agreement (MSA)

Saint-Gobain and denovoMATRIX partnership
Dresden, Germany, 20 June, 2023 / BioInformant / denovoMATRIX GmbH, an innovator in cell and gene therapy manufacturing, and Saint-Gobain Life Sciences have expanded their Master Service Agreement with a special focus on products related to the Stem Cell therapy market. At the same time, Saint-Gobain Life Sciences' investment arm NOVA announces its strategic investment into denovoMATRIX. 

The move is aimed at further cementing the relationship between the parties, in particular leveraging the global reach of Saint-Gobain Life Sciences and the innovative products of the denovoMATRIX team.

“We welcome this investment as a sign of confidence in our technology as well as a milestone marker for our growing market traction in cell therapies.’’

Dejan Hušman
CEO of denovoMATRIX

“We see significant potential for denovoMATRIX’ technology to improve yield and performance in cell and gene therapy applications and enable the next generation of cell culture solutions.”

Minas Apelian
Vice President, External and Internal Venturing, Saint-Gobain

“We are pleased to be a strategic investor in denovoMATRIX. This investment strengthens the partnership, and we continue to explore potential synergies in our products and technologies to better serve our customers in the cell and gene therapy space.”  

Sung Yu
Chief Executive Officer of Saint-Gobain Life Sciences

The collaboration between the companies has been extended through to 2026 and includes specific plans for the development of protocols of products to be used in autologous stem cell therapy market. These include the VueLife® cell culture bags from Saint-Gobain Life Sciences and coated microcarriers from denovoMATRIX.

About denovoMATRIX GmbH


denovoMATRIX serves customers in cell therapy, cultivated meat and pharmaceutical research with tools for supporting cell isolation, manufacturing, and differentiation. Our offering is
focused in three areas, including tailored biomaterials based on our proprietary platform, stem cell biology & characterization services, and finally high potency cell lines.

For more information, visit:

denovoMATRIX GmbH
Dejan Hušman
Tatzberg 47/49
01307 Dresden

About Saint-Gobain

Saint-Gobain Life Sciences


Worldwide leader in light and sustainable construction, Saint-Gobain designs, manufactures and distributes materials and services for the construction and industrial markets. Its integrated solutions for the renovation of public and private buildings, light construction and the decarbonization of construction and industry are developed through a continuous innovation process and provide sustainability and performance. The Group’s commitment is guided by its purpose, “MAKING THE WORLD A BETTER HOME.”

€51.2 billion in sales in 2022
168,000 employees, locations in 75 countries
Committed to achieving Carbon Neutrality by 2050

For more information about Saint-Gobain, visit and follow us on Twitter @saintgobain